List of Antibodies Companies in United Kingdom - 84

At Abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That's why we're constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.

Absolute Antibody Ltd is a UK-based biotechnology company founded in Oxford in August 2012. It specializes in recombinant antibody technology and operates from an ISO 9001:2015 certified facility in Redcar, England. The company focuses on improving antibody reproducibility through genetically defined production methods. The core services include recombinant antibody production using mammalian HEK and CHO cell lines, allowing for animal-free and serum-free manufacturing. They also offer custom engineering, providing antibody sequencing and reformatting into over 180 formats, as well as bespoke projects for pharmaceutical, diagnostic, and academic clients. Their product range features over 21,000 defined recombinant antibodies, ensuring consistency across batches, and includes specialized formats for various applications. Absolute Antibody serves a diverse clientele, including 14 of the top 15 pharmaceutical companies by R&D expenditure, biotechnology firms, and academic institutions. The company emphasizes collaboration in therapeutic antibody development and assay standardization.

Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI)

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers.

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

Arrayjet Ltd is accredited to ISO13485 and providesCRO/CMO liquid handling solutions to support a variety of microarray applications. Their high-speed microarray spotters utilize a patented, non-contact, inkjet technologyfor printing multiplex array-based assays onto slides, Point-Of-Care devices, biochips and microplates.COVID-19: Re-purposed its in-house antibody screening technology to create a population-scale diagnostic program that will help scientists better understand the behavior of the COVID-19 virus and further the rapidity of a global vaccination program.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

aTen Therapeutics is an innovative biotechnology company developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Their technology is focused on antibody discovery and cutting-edge technology development.

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

Badrilla is a biological reagents company focused on providing effective, well validated research antibodies to cardiac proteins, chemistry kits for the study of S-palmitoylation and standards for precise and accurate quantification of immunoassay data. Do you need reagents for your research project that are not currently available? We work with researchers to develop new probes in emerging areas of research, bringing them to the whole community after prompt and thorough characterisation. Approach us with your ideas, we'd like to work together.

BBI Solutions - Serving the Science of Diagnostics BBI Solutions is a leading expert in immunoassay development and manufacturing services, and provides an extensive portfolio of products and technologies to the global research and diagnostic markets. The contribution that the BBI Group makes towards achieving this is by adhering to our Mission; ‘To deliver exceptional products and technologies that people rely on to enjoy a better quality of life. Through innovation, partnership, effective delivery and the collaboration of our people, we constantly strive to help set industry standards, engender trust and build our reputation for excellence

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.

BiVictriX is an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer. Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class. BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications. The Company's initial focus is on the generation of Bi-Cygni Antibody Drug Conjugates (ADCs), with future plans to expand the technology to other therapeutic modalities (Cell engagers and CAR-T).

Cambridge Protein Arrays Ltd. is a SME founded in 2010 and located in Cambridge, United Kingdom. We offer products and customised services in the area of protein microarrays and related areas. We are the distributors of HuProt™ arrays, the largest human protein arrays available, with more than 23,000 human proteins, representing 80% of the human protein coding genome, on a single slide. HuProt™ arrays have been successfully used for antibody and small molecule specificity screening, autoimmune antibody profiling, and interactomics. Cambridge Protein Arrays Ltd. also offers customised protein array services for high throughput screening, autoimmune biomarker validation, and tailored consulting services in the microarrays and antibody area.

Cambridge Research Biochemicals is a biotechnology company that specializes in custom-made peptide and antibody tools.

Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company’s preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

Pharmaceutical Services

Chromocyte is a FREE impartial and innovative online resource for designing complex multi-parameter flow cytometry antibody panels and finding the reagents and antibodies that are required for these and other related techniques. Chromocyte includes intuitive interfaces which highlight the latest flow cytometry products and services and will be an invaluable sales and marketing vehicle for those supplying flow cytometry related products and antibodies. Users can input the configuration of their own flow cytometry instruments and search for antibodies in the context of these. We also have a Core Facility Administration Area which allows flow cytometry configurations to be shared by Users in the same facility. We also offer a unique interface for generating antibody search panels - a great time saver! Chromocyte is somewhat unique in that is is based on the solid and developing academic background in flow cytometry of its Founder. We can therefore provide invaluable insights into current developments and the specific needs of the academic and research communities.

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

DJS Antibodies acquired by Abbvie (10/20/22) DJS Antibodies was founded upon a vision of creating the next generation of antibody therapeutics. The company is dedicated to developing novel therapeutics to treat chronic inflammatory diseases through the discovery and development of antibodies.

Elasmogen is a therapeutic biologics company developing multi-functional products for difficult-to-treat diseases. The company has built a product pipeline that exploits the advantages of its proprietary, patent protected soloMER technology including first-in-class drug conjugates (SDC) and bi-specific products for the treatment of autoimmune diseases. Our oncology assets include a pipeline of differentiated soloMER-targeted RadioPharmaceutical Therapies (RPT) for the treatment of solid tumour cancers.

EmstoPA is a first in class antibody-based reversal agent to treat bleeding caused by tissue plasminogen activator (tPA - Activase®, Alteplase®). tPA is a “clot buster” used to remove the blood clots that cause stroke, pulmonary embolism, and myocardial infarction. In the developed world, tPA is most frequently used to treat acute ischemic stroke where the rates of subsequent intracranial hemorrhage (ICH) are 5-7% . EmstoPA belongs to a class of drugs called anti-fibrinolytics, and and the current market for antifibrinolytics is estimated to be $1,100m /year. Currently no specific tPA reversal agents are in development.

Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

Esox Biologics utilises their extensive knowledge of the aquatic microbiome to provide disease prevention solutions that help improve livestock health and welfare.

Neurodegenerative disorders present a huge societal burden, and one from which few of us remain untouched in some way. Unfortunately, by the time a diagnosis is made, it is often too late and irreversible damage is already done. It is essential that patients get examined as early as possible, and that symptoms get diagnosed accurately. This allows the right patients to receive the right treatments at the right time, to help to slow progression, and mitigate symptoms. Pharma and Biotech companies that are developing disease modifying therapies also have a need for biomarkers for neurodegenerative disorders that can help predict disease presence, monitor disease progression and treatment response. ESP Diagnostics is developing scalable liquid-biopsy tests based upon measurements of specific neurodegenerative disease biomarkers in extracellular vesicles (EVs) extracted from blood, saliva and urine. The ESP biomarker tests will allow early pre-symptomatic detection of neurological disorders such as Parkinson’s Disease, Dementia with Lewy Bodies, and a differential diagnosis of Alzheimer’s. We provide assay services to pharma and biotech companies developing disease-modifying therapies (stratification, disease progression, surrogate endpoints, reverse translation, target engagement), and are developing IVD products for patients, clinicians and healthcare providers worldwide.

Etcembly’s vision is to decode immune repertoires for health and disease. The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally. We are pushing the frontiers to explore the intersection between immunology and machine learning.

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB.

Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client's projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics. We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

Glen Clova Scientific Ltd (GCS) is developing a new generation of Active Biologics to treat inflammatory conditions. We are an ambitious spinout from the University of Dundee aiming to address the global need to make effective treatments available for millions of patients. Our novel Virus-Like-Particle technology is poised to address inherent limitations of the current blockbuster class of Biologic drugs. Our vision is to make high end biotech pharmaceuticals much more accessible to patients than current blockbusters. #Glenclovascientific #Dundee

An introduction to GlycanAge® Our modern lifestyle has drastically changed the way we live and can impact our health for better or for worse. How can you gain a more complete picture of the current state of your health? Science has revealed a significant element that up until recently has largely been overlooked. Your biological age. While you have no control over the process of aging chronologically, your health and lifestyle can have a significant effect on your biological age. Your biological age is therefore not necessarily the same as your chronological age. Only about 54% of biological aging is determined by your genes, with about 46% being influenced by environmental factors. GlycanAge is a simple, ground-breaking test that analyses your glycobiology. Taking a GlycanAge® test is a vital step to improving your health. Your test results enable you to become aware of and monitor your biological age. This not only offers you an accurate insight into the current state of your health but can give you the powerful tool to make an informative decisions about lifestyle choices and changes.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

At ichorbio, we are passionate about animals and believe there is a better way to do in vivo research. For us, the most important consideration was that our antibodies for in vivo use have the lowest possible impact on the animals they are being used in. This is how our mission was born: to create the best antibodies for in vivo research. To achieve our mission, we have created products that have lower endotoxin, higher purity and lower aggregation than other antibodies currently available on the market. Our antibodies adhere to all the same criteria as many of the larger manufacturers from a quality perspective with the added benefit that you can feel confident that you are doing the best for your animals. Best selling antibodies: RMP1-14: https://ichor.bio/ich1132-compared-to-be0146 RMP1-14 LALAPG: https://ichor.bio/revolutionize-your-pd-1-research-with-rmp1-14-lalapg

Iksuda Therapeutics is a biotechnology company focussed on the development of a new generation of antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of non-prodrug/prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform.

ILC Therapeutics (ILCT) is a Scottish-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of hybrid interferon drugs. The company is focused on modulating the Innate Immune System through the development of innovative therapies. ILC Therapeutics has raised significant funding to advance its lead interferon drug candidate and has announced its first international collaboration. The company is dedicated to revolutionizing the treatment of various diseases through its cutting-edge research and development efforts.

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company’s lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.

Intract Pharma is a biotechnology company innovating in the field of oral delivery of complex proteins such as monoclonal antibodies with a special focus on treatment of gastrointestinal and systemic immune-mediated inflammatory diseases. Intract is applying it’s Phloral™ and Soteria™ technology platform for precision delivery of proteins to the colon for local tissue and systemic immunomodulation. Our vision is to transform care for millions of patients suffering from chronic diseases by converting their potent injectable biologic medicines into safe, effective and convenient take-at-home pills.

Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH single-domains. Sometimes known as nanobodies, sdAbs, or heavy-chain single domains, VHHs offer exceptional robustness, flexibility, and manufacturability - , accelerating antibody discovery and development. Their versatility makes them suitable for use in bi-specifics, ADCs, cell and gene therapies, targeted protein degraders, diagnostics and much more. We believe VHHs are the future of medicine - and our synthetic technology gives our VHH libraries the edge in accelerating your drug discovery and development programmes so you can focus on developing the ideas and technologies that could change lives. Offering the largest and most diverse synthetic VHH (nanobody) libraries available on the market, combined with our proprietary CIS display technology, means that VHH discovery with at Isogenica can interrogate up to 1000x more VHH antibody sequences than other display technologies. Our knowledge and experience of VHH, combined with our synthetic libraries’ size and diversity help deliver better antibodies faster, with higher affinity and broader IP coverage. Our in-house experts tailor each project to meet bespoke needs, allowing us to provide industry-disrupting antibody solutions to our partners in around half the time of a traditional animal immunisation campaign. Originally founded near Cambridge, UK over 25 years ago, Isogenica has evolved to become The VHH Company. As an established and trusted antibody partner, our track record of success includes dozens of lead panels including three clinical-stage assets. This bespoke and collaborative approach to antibody discovery extends to how we do business - working flexibly with different partners with uncompromising passion and dedication.

Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of genetically modified MSCs.

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Their mission is to accelerate the discovery of next-generation therapeutic antibodies that have been designed for maximum potential. They are headquartered in London and their core technology platform, EVA™, enables the development of novel protein therapeutics.

Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent. Such a solution has applications in a number of high-value sectors including health, food, defence and security. LDL has also established development partnerships with a number of end users including clinical microbiology, food producers and defence medicine.

Macomics is a biotechnology company that focuses on developing precision medicines to modulate macrophages for the treatment of cancer.

Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

Medicxi is an international investment firm focused on the life sciences sector. It wasestablished in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

MediSieve is a London biotech start-up developing Magnetic Haemofiltration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available for this product in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. Magnetic Haemofiltration has already been shown to rapidly, specifically, and effectively remove IL-6 from human plasma. The technology has completed pre-clinical validation, including animal studies, and is expected to start clinical studies in Q2 2022. MediSieve has raised £4M in equity funding and over £4M in non-dilutive grants. Seeking a further £8M at Series A to support pivotal clinical trials and regulatory approvals. EIS eligible. The company has been featured in numerous online and print media articles, including the Sunday Telegraph, Daily Mail, and Wired Magazine, and been winner or finalist in several start-up competitions such as Pitch@Palace, MassChallenge, OBN Awards, TCT Magazine Awards and CMS Healthcare Startup of the Year. Recently, our founder George Frodsham was awarded BBSRC Innovator of the Year and MIT Innovators Under 35.

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner. Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options. Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates. Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence. Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career.

Myricx Bio is a biotech company headquartered in London, focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs). They are focused on the discovery and development of a completely novel class of selective cytotoxic payloads for ADCs.

NanoSyrinx is a cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector.

NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond

NunaBio is a privately-owned specialist DNA synthesis and development company. We are engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. The company has built a solid reputation for its R&D flexibility and innovative approach to complex and challenging projects. NunaBio's core expertise is research and development into cell-free DNA synthesis, process optimisation, route design, scale-up and small-scale manufacture for clinical studies.

Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune is headquartered in the UK, with a discovery research centre in Dortmund, Germany and an office in Cambridge MA, USA.

Orla Protein Technologies is a leader in Life Science, specializing in recombinant protein design, engineering, and manufacture for surface applications.

OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds. The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK. Ossianix was founded by Frank S Walsh, Corey Goodman and Lynn Rutkowski who have had distinguished careers in academia, Pharma and Biotech and bring a wealth of experience to the problem of delivering the next generation of Biologics products. The company started operations in 2012 with funding from Lundbeck Pharmaceuticals, BioAdvance and the ALS Association. Current programs focus on neurodegereration, neurooncology, ALS, pain and botulism.

Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.

Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).

Oxford Genetics is a synthetic biology company focused on developing novel technologies to overcome challenges associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.

Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).

ProImmune's mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.

For when you need it all. We're here. We know scientists give it their all every day to reach their goals. Wherever your research takes you, Proteintech provides all of the antibodies you need to help you do that. All types and forms of antibodies are in stock for your experiment. We’ll be there for every step of your journey. With our GMP capabilities and recombinant custom antibody platform, we can provide the support to scale up from bench to clinic. Search the full catalog at ptglab.com.

We are a global, clinical stage pharmaceutical company with a mission to develop and commercialise clinically meaningful, novel therapeutics that will bring life-enhancing benefits to children across the world. Our first development program focuses on Hu14.18, a humanised anti-GD2 monoclonal antibody, licensed from St. Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel key Phase II trial incorporated the addition of Hu14.18 antibody to standard induction chemotherapy and demonstrated outstanding outcomes in patients with newly diagnosed high-risk neuroblastoma, with a 3-year event-free (EFS) and overall survival (OS) of 73.7% and 86.0% respectively. Renaissance Pharma Ltd is led by an Executive Team with extensive experience in the development, approval and commercialisation of oncology and rare disease products. We invite industry manufacturers, formulators, researchers and investors to collaborate with us. Together we can build new partnerships to improve patients' lives. To discuss partnership opportunities, please contact info@renaissancepharma.co.uk We invite industry manufacturers, formulators, researchers & investors to collaborate with us. Together we can build new partnerships to improve patients' lives.

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics’ portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of: 1. Midkine antibodies with significant in vivo efficacy and toxicology studies; 2. Midkine RNA therapeutics with novel anti-cancer gene editing action; 3. MK cell therapy with direct and NK-mediated anti-cancer action; and 4. siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

RQ Biotechnology is making instant immunity a reality for vulnerable people. As the leading passive immunization discovery company, we partner with pharmaceutical companies to develop our antibodies into protect against infectious diseases where vaccines cannot. RQ Bio is dedicated to developing medicines based on potent broad-spectrum mAbs to provide instant and long-lasting protection for vulnerable people at risk of severe disease or death from current and future viral infections.

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST. This breakthrough technology is currently being applied to the world’s most prevalent diseases and infections where earlier and more prevalent diagnoses can make the biggest impact. Founded with the goal of developing PCR accurate point-of-care diagnostics for the world’s most deadly diseases, Senzo Health builds high sensitivity, low-cost, real-time testing technologies. PRICE Laboratory-based diagnostics are expensive, to the individual, the insurer, and the system. By lowering the price of modern diagnostics, we dramatically increase their use and value within healthcare. ACCURACY The Senzo Amplified Lateral Flow test is PCR-accurate. This means that for the first time we can bring testing for a range of new infections and diseases out of the laboratory and closer to the patient enabling a revolution in both diagnostics and treatments. SIMPLICITY Current diagnostics are too complex. From appointments to samples to laboratories to results. By simplifying diagnostics and bringing accurate and real-time testing to the patient, we can save money, save resources and save lives. SPEED Testing is about accurate results. The faster we can return a diagnosis, the sooner we can begin a treatment. Currently, patients and health care professionals often wait days for results. Real-time testing changes this forever, removing the gaps between consultation, testing, data and treatment. ACCESSIBILITY Accurate diagnostics today remain unevenly distributed. The only way to bring testing to patients in lower-income areas is to replace the complex central laboratory model with an affordable point-of-care diagnostics system without sacrificing accuracy.

Severn Biotech is a microbiology company that specializes in laboratory services and biotechnology.

We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and are maximizing the potential of our technology through research partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, we have fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

Source BioScience, comprised of Source LDPath and Source Genomics, provides industry-leading laboratory services in Genomics and Histopathology, partnering with biotechnology, pharmaceutical, healthcare and academia. Source LDPath provides an end-to-end clinical diagnostic service, from histopathology, including digital pathology and AI, through to molecular diagnostic services. Source LDPath already supports over 85 NHS Trusts and a comprehensive network of Private Healthcare clinics to expand their diagnostic capabilities, ensuring diagnostic results are delivered within clinically actionable timeframes. Source LDPath brings pioneering expertise in digital pathology and AI implementation, helping NHS pathology departments digitise their workflows for streamlined operations and greater diagnostic reporting capacity, tailoring integration touchpoints to the specific requirements of the Hospital or Trust. • Cellular and digital pathology wet laboratory processing • Reporting - access a pool of over 200 specialist consultant pathologists • MDM and Second Opinions • Digital Implementation Support with AI integration • Connectivity and LIMS integration with Source HIVE™ Source Genomics provides a broad portfolio of multi-omic services, delivering high-quality data in Genomics, Spatial Transcriptomics, Proteomics and Epigenomics. Market-leaders in Sanger Sequencing and Next-Generation Sequencing Services, Source Genomics delivers bespoke laboratory expertise to excel your project at rapid turnaround times. • Sanger Sequencing • NGS - WGS, WES, RNA-seq • Oxford Nanopore Sequencing • Olink proteomics • Optical Genome Mapping • 10x Genomics Visium • Bioinformatics • And more Contact us today at enquiries@sourcebioscience.com.

Spirea Limited is a Cambridge-based company created to advance a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles. Spirea will use its innovative technology to enable a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumours.

Stratech Scientific Ltd. is a UK-based distributor of life science research tools, established in 1983 by Sue Hallett. The company specializes in overcoming logistical challenges related to temperature-sensitive biological products. With a revenue of $8.5 million and a team of approximately 20 employees, Stratech has built a reputation for reliability and customer-centric services, offering a money-back guarantee on all products. Stratech distributes over 90,000 life science research tools globally, including antibodies, molecular biology tools, sample preparation reagents, and specialized biochemicals. The company serves a diverse customer base, including academic, pharmaceutical, and biotechnology research laboratories. It has longstanding relationships with institutions like the John Innes Centre and supports manufacturers in entering European markets. Stratech is known for its expertise in cold-chain distribution and provides technical support tailored to various research applications.

Symbiosis Pharmaceutical Services is a contract manufacturing organisation (CMO) that specialises in the GMP manufacture and sterile fill/finish of vials for clinical trials and low-volume commercial supply. Regulatory compliance, technical capability and operational flexibility are at its core. Manufacturing takes place in a purpose-built MHRA-licensed and FDA approved facility, enabling the CMO to handle products that require aseptic liquid filling and lyophilisation for a range of complex biologics, viral vectors for use in gene therapies and small molecule drugs. Offering fast access to manufacturing slots and accelerated release of drug product, Symbiosis is primed to meet demand for small-scale, fast-turnaround drug product manufacturing, while maintaining regulatory compliance to the highest standards. Symbiosis specialises in the sterile fill/finish of biologic and small molecule products into vials, which are either liquid or lyophilised formulations. Capabilities include the ability to handle and fill antibodies, proteins, peptides, nucleic acids, cytotoxic, cytostatic and highly potent APIs including ADCs along with conventional small molecules. Symbiosis saves our clients invaluable development time. With short lead times to manufacture and faster release of sterile drug product, we get you into phase I/II quickly. Our focus is service excellence through flexibility, responsiveness and timeliness. If you need a drug filled aseptically, come and speak with Symbiosis...we will exceed your expectations.

A new approach to halting the spread of tau pathology and destruction of nerve cells in the brain Precision immunotherapy for the treatment of tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP)

Tiziana Life Sciences is a dual-listed* (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver. Our clinical pipeline includes drug assets for Crohn's Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. *Note: Our market cap for TLSA is likely not accurate because its shares are listed on both the London Stock Exchange and the NASDAQ.

Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.